{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:04:46Z","timestamp":1789722286654,"version":"4.0.1"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1515\/dmpt-2026-0047","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:56:28Z","timestamp":1789721788000},"source":"Crossref","is-referenced-by-count":0,"title":["Leaders in pharmacogenetics: Leif Bertilsson"],"prefix":"10.1515","author":[{"given":"Ingrid","family":"Fricke-Galindo","sequence":"first","affiliation":[{"name":"Pneumogenomics Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas , Mexico City , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-3223","authenticated-orcid":false,"given":"Fernanda","family":"Rodrigues-Soares","sequence":"additional","affiliation":[{"name":"Departamento de Patologia , Gen\u00e9tica e Evolu\u00e7\u00e3o, Instituto de Ci\u00eancias Biol\u00f3gicas e Naturais, Universidade Federal do Tri\u00e2ngulo Mineiro , Uberaba , Brazil"},{"name":"RIBEF Iberoamerican Network of Pharmacogenetics and Pharmacogenomics , Badajoz , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5663-7081","authenticated-orcid":false,"given":"Adri\u00e1n","family":"LLerena","sequence":"additional","affiliation":[{"name":"RIBEF Iberoamerican Network of Pharmacogenetics and Pharmacogenomics , Badajoz , Spain"},{"name":"University of Extremadura Medical School and Health Sciences , Badajoz , Spain"},{"name":"Dpt. Clinical Pharmacology, Unit of Pharmacogenomics and Personalized Medicine, Badajoz University Hospital, Extremadura Health Service , Badajoz , Spain"},{"name":"INUBE Biosanitary University Research Institute , Badajoz , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091808561996852_j_dmdi-2026-0047_ref_001","doi-asserted-by":"crossref","unstructured":"\u00c5sberg, M, Thor\u00e9n, P, Tr\u00e4skman, L, Bertilsson, L, Ringberger, V. \u201cSerotonin depression\u201d\u2013a biochemical subgroup within the affective disorders? Sci 1976;191:478\u201380. https:\/\/doi.org\/10.1126\/SCIENCE.1246632.","DOI":"10.1126\/science.1246632"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_002","doi-asserted-by":"crossref","unstructured":"Thor\u00e4n, P, \u00c5sberg, M, Bertilsson, L, Mellstr\u00fcm, B, Sj\u00fcqvist, F, Tr\u00e4skman, L, et al.. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980;37:1289\u201394. https:\/\/doi.org\/10.1001\/ARCHPSYC.1980.01780240087010.","DOI":"10.1001\/archpsyc.1980.01780240087010"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_003","doi-asserted-by":"crossref","unstructured":"Tr\u00e4skman, L, \u00c5sberg, M, Bertilsson, L, Sj\u00fcstrand, L. Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981;38:631\u20136. https:\/\/doi.org\/10.1001\/ARCHPSYC.1981.01780310031002.","DOI":"10.1001\/archpsyc.1981.01780310031002"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_004","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Dengler, HJ, Eichelbaum, M, Schulz, HU. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 1980;17:153\u20135. https:\/\/doi.org\/10.1007\/BF00562624.","DOI":"10.1007\/BF00562624"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_005","doi-asserted-by":"crossref","unstructured":"Eichelbaum, M, Bertilsson, L, S\u00e4we, J, Zekorn, C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982;31:184\u20136. https:\/\/doi.org\/10.1038\/CLPT.1982.29.","DOI":"10.1038\/clpt.1982.29"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_006","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Aberg\u2010Wistedt, A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983;15:388\u201390. https:\/\/doi.org\/10.1111\/J.1365-2125.1983.TB01518.X.","DOI":"10.1111\/j.1365-2125.1983.tb01518.x"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_007","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Aberg\u2010Wistedt, A, Gustafsson, LL, Nordin, C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478\u201380. https:\/\/doi.org\/10.1097\/00007691-198512000-00021.","DOI":"10.1097\/00007691-198512000-00021"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_008","doi-asserted-by":"crossref","unstructured":"Nordin, C, Siwers, B, Benitez, J, Bertilsson, L. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 1985;19:832\u20135. https:\/\/doi.org\/10.1111\/J.1365-2125.1985.TB02723.X.","DOI":"10.1111\/j.1365-2125.1985.tb02723.x"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_009","doi-asserted-by":"crossref","unstructured":"Br\u00f8sen, K, Klysner, R, Gram, LF, Otton, SV, Bech, P, Bertilsson, L, et al.. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine\/debrisoquine polymorphism. Eur J Clin Pharmacol 1986;30:679\u201384. https:\/\/doi.org\/10.1007\/BF00608215.","DOI":"10.1007\/BF00608215"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_010","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Alm, C, De Carreras, CL, Widen, J, Edman, G, Schalling, D, et al.. Debrisoquine hydroxylation polymorphism and personality. Lancet (London, England) 1989;1:555. https:\/\/doi.org\/10.1016\/S0140-6736(89)90094-9.","DOI":"10.1016\/S0140-6736(89)90094-9"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_011","doi-asserted-by":"crossref","unstructured":"Llerena, A, Edman, G, Cobaleda, J, Ben\u00edtez, J, Schalling, D, Bertilsson, L, et al.. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993;87:23\u20138. https:\/\/doi.org\/10.1111\/J.1600-0447.1993.TB03325.X.","DOI":"10.1111\/j.1600-0447.1993.tb03325.x"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_012","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Dahl, ML, Sj\u00f6qvist, F, \u00c5berg-Wistedt, A, Humble, M, Johansson, I, et al.. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (London, England) 1993;341:63. https:\/\/doi.org\/10.1016\/0140-6736(93)92546-6.","DOI":"10.1016\/0140-6736(93)92546-6"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_013","doi-asserted-by":"crossref","unstructured":"Johansson, I, Lundqvist, E, Bertilsson, L, Dahl, ML, Sj\u00f6qvist, F, Ingelman-Sundberg, M, et al.. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825\u20139. https:\/\/doi.org\/10.1073\/PNAS.90.24.11825.","DOI":"10.1073\/pnas.90.24.11825"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_014","doi-asserted-by":"crossref","unstructured":"Dal\u00e9n, P, Dahl, ML, Bernal Ruiz, ML, Nordin, J, Bertilsson, L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63:444\u201352. https:\/\/doi.org\/10.1016\/S0009-9236(98)90040-6.","DOI":"10.1016\/S0009-9236(98)90040-6"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_015","doi-asserted-by":"crossref","unstructured":"Bertilsson, L. Geographical\/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192\u2013209. https:\/\/doi.org\/10.2165\/00003088-199529030-00005.","DOI":"10.2165\/00003088-199529030-00005"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_016","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Dahl, ML, Dal\u00e9n, P, Al-Shurbaji, A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111\u201322. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01548.x.","DOI":"10.1046\/j.0306-5251.2001.01548.x"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_017","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Lou, YQ, Du, YL, Liu, Y, Kuang, TY, Liao, XM, et al.. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388\u201397. https:\/\/doi.org\/10.1038\/clpt.1992.38.","DOI":"10.1038\/clpt.1992.38"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_018","doi-asserted-by":"crossref","unstructured":"Johansson, I, Oscarson, M, Yue, QY, Bertilsson, L, Sj\u00f6qvist, F, Ingelman-Sundberg, M, et al.. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46. https:\/\/doi.org\/10.1016\/s0026-895x(25)09721-4.","DOI":"10.1016\/S0026-895X(25)09721-4"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_019","doi-asserted-by":"crossref","unstructured":"Masimirembwa, C, Bertilsson, L, Johansson, I, Hasler, JA, Ingelman-Sundberg, M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656\u201361. https:\/\/doi.org\/10.1016\/0009-9236(95)90228-7.","DOI":"10.1016\/0009-9236(95)90228-7"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_020","doi-asserted-by":"crossref","unstructured":"Dahl-Puustinen, ML, Lid\u00e9n, A, Alm, C, Nordin, C, Bertilsson, L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78\u201381. https:\/\/doi.org\/10.1038\/CLPT.1989.109.","DOI":"10.1038\/clpt.1989.109"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_021","doi-asserted-by":"crossref","unstructured":"LLerena, A, Alm, C, Dahl, ML, Ekqvist, B, Bertilsson, L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92\u20137. https:\/\/doi.org\/10.1097\/00007691-199204000-00003.","DOI":"10.1097\/00007691-199204000-00003"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_022","doi-asserted-by":"crossref","unstructured":"Dahl, ML, Llerena, A, Bondesson, U, Lindstr\u00f6m, L, Bertilsson, L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994;37:71\u20134. https:\/\/doi.org\/10.1111\/j.1365-2125.1994.tb04242.x.","DOI":"10.1111\/j.1365-2125.1994.tb04242.x"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_023","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Carrillo, J, Dahl, M, Llerena, A, Alm, C, Bondesson, U, et al.. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471\u20133. https:\/\/doi.org\/10.1111\/J.1365-2125.1994.TB04385.X.","DOI":"10.1111\/j.1365-2125.1994.tb04385.x"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_024","doi-asserted-by":"crossref","unstructured":"Ghotbi, R, Christensen, M, Roh, HK, Ingelman-Sundberg, M, Aklillu, E, Bertilsson, L, et al.. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007;63:537\u201346. https:\/\/doi.org\/10.1007\/S00228-007-0288-2.","DOI":"10.1007\/s00228-007-0288-2"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_025","doi-asserted-by":"crossref","unstructured":"Sanz, EJ, Vill\u00e9n, T, Alm, C, Bertilsson, L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989;45:495\u20139. https:\/\/doi.org\/10.1038\/clpt.1989.63.","DOI":"10.1038\/clpt.1989.63"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_026","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Henthorn, TK, Sanz, E, Tybring, G, S\u00e4we, J, Vill\u00e9n, T, et al.. Importance of genetic factors in the regulation of diazepam\u00a0metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348\u201355. https:\/\/doi.org\/10.1038\/CLPT.1989.40.","DOI":"10.1038\/clpt.1989.40"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_027","doi-asserted-by":"crossref","unstructured":"Andersson, T, Reg\u00e5rdh, CG, Dahl-Puustinen, ML, Bertilsson, L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415\u20136. https:\/\/doi.org\/10.1097\/00007691-199007000-00020.","DOI":"10.1097\/00007691-199007000-00020"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_028","doi-asserted-by":"crossref","unstructured":"Chang, M, Dahl, ML, Tybring, G, G\u00f6tharson, E, Bertilsson, L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358\u201363. https:\/\/doi.org\/10.1097\/00008571-199512000-00004.","DOI":"10.1097\/00008571-199512000-00004"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_029","doi-asserted-by":"crossref","unstructured":"Sim, SC, Risinger, C, Dahl, ML, Aklillu, E, Christensen, M, Bertilsson, L, et al.. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103\u201313. https:\/\/doi.org\/10.1016\/j.clpt.2005.10.002.","DOI":"10.1016\/j.clpt.2005.10.002"},{"key":"2026091808561996852_j_dmdi-2026-0047_ref_030","doi-asserted-by":"crossref","unstructured":"Bertilsson, L, Kalow, W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther 1993;53:608\u201310. https:\/\/doi.org\/10.1038\/CLPT.1993.77.","DOI":"10.1038\/clpt.1993.77"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2026-0047\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2026-0047\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:56:49Z","timestamp":1789721809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2026-0047\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":30,"alternative-id":["10.1515\/dmpt-2026-0047"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2026-0047","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}